GTx And UTRF Enter Into Exclusive License Agreement To Develop SARD Drug Candidate To Treat Castration-Resistant Prostate Cancer
University of Tennessee Research Foundation
Technology Transfer & Licensing
GTx And UTRF Enter Into Exclusive License Agreement To Develop SARD Drug Candidate To Treat Castration-Resistant Prostate Cancer